In Vitro Diagnostics in a Recession
IVD Market Forecasts, Analysis and Success Strategies
Publication Date: May 2009
Publisher: Kalorama Information
Pages:
115
|
Price
£1,965.00
approximately: $2,994 | €2,222
Buy now >>
(managed by Piribo)
|
It is commonly asserted that in vitro diagnostics is a
recession-proof industry. Kalorama Information's lead diagnostic analyst
Shara Rosen tests that assumption and provides strategic conclusions in
Shara Rosen's new report In Vitro Diagnostics in a Recession.
The economic problems that began slowing the US economy keep
spreading, with Europe and Japan following America into recession. The
US is experiencing high unemployment rate and increased numbers of
uninsured workers. But what impact is the downturn having on in vitro
diagnostic companies? What are the best areas of IVD and the best world
markets? How should companies price and market their products? What are
key companies in the market doing at this time?
Among the topics covered in this report:
- Current Market Estimates for Major Categories of IVD.
- Category Forecasts to 2014
- Hospital Woes, Uninsured Patients, Payor Stress, and Other
Trends industry observers need to know about.
- Current World Economic Conditions US, Europe and Emerging
MarketsObama Administration Healthcare Reform Boom or Bust for IVD?
- Mergers and Acquisitions: Abbot - Ibis, QIAGEN - Corbett Life
Science, J&J / Amic and several other competitive moves.
- Collaborations: Luminex and BD Tripath, Geisinger Health System
and Celera, Sysmex and Epigenomics and other partnerships enacted as
companies pool limited resources.
- Market Expansions: StatSensor Creatinine Meter (TM), Dako and
BMS partnership and Others.
- New Testing Products Launched: BD Focal Point, Aureon's Prostate
Px+, New Abbott Marker for AKI and other new tests.
- Lab Service Commercialization Activities
- Lab IT Activity and the Involvement of High Tech Players such as
Google and IBM.
- Success Strategies That are Working in 2009
Shara Rosen goes beyond just assessing the market and presents
actions that IVD companies can take to assure growth in uncertain times.
The report has a special focuses on developments in the United States
since this is the largest single market for IVD products, but there is
discussion of emerging world markets as well.
The following companies who have engaged in relevant competitive
activities in recent months were profiled in this report:
- Abbott Diagnostics
- Beckman Coulter Inc.
- Becton, Dickinson and Company (BD)
- bioMerieux Inc.
- Celera Corporation
- Cellestis Ltd
- Cepheid
- Clarient Inc. (formerly ChromaVision)
- deCode Genetics Inc.
- Genomic Health
- Gen-Probe Inc.
- Immucor, Inc.
- Inverness Medical Innovations
- Luminex Corporation
- Monogram Biosciences, Inc.
- Nanogen
- Ortho Clinical Diagnostics (OCD)
- Qiagen N.V.
- Quidel Corporation
- Roche Diagnostics
- Seegene, Inc.
- Sequenom, Inc.
- Siemens Medical Solutions Diagnostics
- Sysmex Corporation
- Vermillion/Ciphergen Biosystems Inc.
This Kalorama Information report is a work of primary research.
Although secondary sources were used, the analyst's years of experience,
interviews with industry experts and the latest findings of the 2009
Diagnostic Marketing Association Conference in Chicago IL were part of
this report's foundation.
Buy now >>
Contents
- Chapter ONE: Executive Summary
- Scope and Methodology
- Market Trends
- World Demand for Diagnostics
- Keys to Success
- Chapter TWO: Introduction
- Background
- Marketing in a recession - what the experts say about the
4Ps
- Obama's new deal - boom and bust
- Musings on what form a reformed U.S. system might take
- Status quo and future - impressing investors in a bear
market
- Chapter THREE: Market Trends/Demand Analysis
- Hospital financing
- The role of new deal for the insured, uninsured and
underinsured
- Payer response to economic stress
- Demand for esoteric tests
- World market for IVD tests and services
- 2009 Market Estimates (N. America, EU West Europe, Japan,
China, Latin America, India, EU East Europe, ROW)
- 2014 Market Forecasts (N. America, EU West Europe, Japan,
China, Latin America, India, EU East Europe, ROW)
- Economic Conditions in United States of America
- Economic Conditions in Europe
- Economic Conditions in Japan
- Economic Conditions in China
- Chapter FOUR: Market Overview/Supply Analysis
- Market Analysis, revenue estimates 2007 - 2015
- IVD Sectors Revenues
- Clinical Chemistry,
- Immunoassays - non isotopic Infectious Diseases
- Other Immunos
- Blood Bank Screening
- Hematology
- Microbiology (ID/AST)
- Molecular Microbiology
- Radioimmunoassays
- Coagulation
- Histology/Cytology
- Nucleic Acid Assays
- Blood Grouping/Typing
- Blood Bank Molecular
- Flow Cytometry
- POC -OTC diabetes
- POC -OTC other
- POC -Professional/Hospital
- IVD Events
- New Tests and Technologies
- Abbott Diagnostics
- Adnavance Technologies
- Arbor Vita Corporation
- Arcxis Biotechnologies and Roche
- Assay Designs
- Aureon Laboratories
- Bayer Healthcare
- BD Diagnostics
- bioMrieux
- BRAHMS
- Caris Diagnostics
- CISBIO Bioassays
- Decision Biomarkers
- DexCom
- Diagnostic HYBRIDS
- Fujirebio Diagnostics
- GeneNews
- InVivoScribe Technologies
- Network Biosystems
- Acquisitions, Mergers
- Abbott Diagnostics-Ibis
- Beckman Coulter-Nephromics
- Exiqon A/S-Oncotech
- GE Healthcare-Whatman
- Others
- Collaborations
- Market Expansion Activities
- Lab Services
- Lab Information
- Google
- IBM
- Intel Corporation
- General Data Company Technology
- Chapter FIVE: Company Profiles
- Abbott Diagnostics
- Beckman Coulter Inc.
- Becton, Dickinson and Company (BD)
- bioMerieux Inc.
- Celera Corporation
- Cellestis Ltd
- Cepheid
- Clarient Inc. (formerly ChromaVision)
- deCode Genetics Inc.
- Genomic Health
- Gen-Probe Inc.
- Immucor, Inc.
- Inverness Medical Innovations
- Luminex Corporation
- Monogram Biosciences, Inc.
- Nanogen
- Ortho Clinical Diagnostics (OCD)
- Qiagen N.V.
- Quidel Corporation
- Roche Diagnostics
- Seegene, Inc.
- Sequenom, Inc.
- Siemens Medical Solutions Diagnostics
- Sysmex Corporation
- Vermillion/Ciphergen Biosystems Inc.
- Chapter SIX: Conclusion
- Pricing Strategy
- Marketing Strategy
- Supply and Demand
- TABLE OF EXHIBITS
- CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Growth Rates Compared: World Regions
- CHAPTER TWO: INTRODUCTION
- Table 2-1: Selected IVD Venture Investments
- Chapter THREE: MARKET TRENDS/DEMAND ANALYSIS
- Table 3-1: Number of People Worldwide Who Get Chronic
Diseases Every Year
- Table 3-2: Percent Change in Industrial Productivity, by
Country or Region, December 2007 to December 2008
- Table 3-3: Worldwide In Vitro Diagnostic Reagent Sales by
country, 2009-2014
- Table 3-4: Europe Unemployment Rates and % change in GDP
- Chapter FOUR: Market Overview/Supply Analysis
- Table 4-1
- Worldwide In Vitro Diagnostic Reagent Sales by Product
Segment, 2009-2014 (Clinical Chemistry, Immunoassays, Blood Bank
Screening, Hematology, Microbiology, Radioimmunoassays,
Coagulation, Histology/Cytology, Nucleic Acid Assays, Blood
Grouping/Typing, Blood Bank Molecular, Flow Cytometry, POC OTC
diabetes, POC, OTC Other, POC, Professional/Hospital)
- Chapter SIX: Conclusion
- Table 6-1: Pricing Structures That Create Value for the
Customer
Buy now >>
To top
|
|
|